Literature DB >> 24022820

Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.

G Eymin1, A K Jaffer.   

Abstract

Stroke and venous thromboembolism (VTE) are serious and preventable thrombotic events in patients with atrial fibrillation (AF) and who undergo surgery or hospitalization, respectively. Nevertheless, thromboprophylaxis remains greatly underused. The National Quality Forum, the Agency for Healthcare Research and Quality, and the Joint Commission have developed quality measures aimed at improving the provision of appropriate thromboprophylaxis. Reporting of these measures will increasingly become mandatory and hospitals will face financial penalties for failure to report. The approval of new oral anticoagulants (direct thrombin and factor Xa inhibitors) may simplify provision of thromboprophylaxis and eventually increase adherence to guidelines and quality measures. The primary objective of this review is to present evidence supporting the core quality measures for VTE prevention and stroke prevention in patients with AF. The secondary objective is to familiarize physicians with the new anticoagulants and their approved indications. This review concludes with a brief description of the Society of Hospital Medicine online resources for VTE prevention as well as recommendations for planning and implementation of quality improvement in the management of VTE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24022820     DOI: 10.1007/s11239-013-0874-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  71 in total

1.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Heuzey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2011-02-14       Impact factor: 29.690

3.  Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention.

Authors:  Steven L Cohn; Ayoola Adekile; Vishal Mahabir
Journal:  J Hosp Med       Date:  2006-11       Impact factor: 2.960

4.  Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines.

Authors:  D M Arnold; S R Kahn; I Shrier
Journal:  Chest       Date:  2001-12       Impact factor: 9.410

5.  Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop.

Authors:  Gary E Raskob; Roy Silverstein; Dale W Bratzler; John A Heit; Richard H White
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

6.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

Review 7.  Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.

Authors:  Arlene Tran; Angela Cheng-Lai
Journal:  Cardiol Rev       Date:  2011 May-Jun       Impact factor: 2.644

8.  Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.

Authors:  Larry B Goldstein; Robert Adams; Mark J Alberts; Lawrence J Appel; Lawrence M Brass; Cheryl D Bushnell; Antonio Culebras; Thomas J Degraba; Philip B Gorelick; John R Guyton; Robert G Hart; George Howard; Margaret Kelly-Hayes; J V Ian Nixon; Ralph L Sacco
Journal:  Stroke       Date:  2006-05-04       Impact factor: 7.914

9.  The natural history of lone atrial fibrillation. A population-based study over three decades.

Authors:  S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

10.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

View more
  1 in total

1.  Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials.

Authors:  Thomas Agoritsas; Emma Iserman; Nicholas Hobson; Natasha Cohen; Adam Cohen; Pavel S Roshanov; Miguel Perez; Chris Cotoi; Rick Parrish; Eleanor Pullenayegum; Nancy L Wilczynski; Alfonso Iorio; R Brian Haynes
Journal:  Implement Sci       Date:  2014-09-20       Impact factor: 7.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.